Clinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study

Table 5 Remission and relapse of patients in the two groups (n, %)

	Normal group (n = 65)	Abnormal group (n = 148)	P value
Managements
Methods
Steroid monotherapy	26 (40.0)	81 (54.7)	0.029a
Steroid and immunomodulator	14 (21.5)	30 (20.3)
Endoscope or surgery	12 (18.5)	9 (6.1)
Others1	13 (20.0)	28 (18.9)
Duration of steroid (wk)	8 (6-9)	8 (6-9)	0.750
Dose of steroid (prednisolone, mg/d)	42.5 (40-100)	40 (30-50)	0.200
Remission	65 (100.0)	145 (98.0)	0.555
	Normal group (n = 4)	Abnormal group (n = 26)	P value
Relapse
Relapse rate	4/58 (6.2)	26/135 (17.6)	0.030a
Relapse duration (mo)	25 (13.5-52.3)	43 (16.3-72)	0.442
Lesions of relapse
Pancreas	4 (100.0)	21 (80.8)	0.337
Extrapancreatic organs	0 (0.0)	5 (19.2)
Times of relapse
Once	4 (100.0)	22 (84.6)	0.399
More than one time	0 (0.0)	4 (15.4)
Initial therapies
Steroid monotherapy	1 (25.0)	15 (57.7)	0.129
Steroid and immunomodulator	2 (50.0)	2 (7.70)
Endoscope or surgery	0 (0.00)	2 (7.70)
Others1	1 (25.0)	7 (26.9)
Therapies for relapse
Steroid monotherapy	2 (50.0)	18 (69.2)	0.410
Steroid and immunomodulator	1 (25.0)	2 (7.70)
Endoscope or surgery	1 (25.0)	2 (7.70)
Others1	0 (0.00)	4 (15.4)

^aP < 0.05 vs normal group.

¹Others: Hepatic protectors, antibiotics and proton pump inhibitors.